Lead party: Adjuvant Capital (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: 54Gene, Inc. (private company) · Sector: Healthcare, Biotechnology · Countries of operation: Nigeria
Transaction type: Investment · Asset class: Venture Capital · Strategy: Venture Equity · Instrument: Equity · Round: Series A · Deal amount: US$15m · Fund: Adjuvant Global Health Technology Fund LP
Lead investor/buyer: Adjuvant Capital · Investors/buyers: Adjuvant Capital, Raba Capital, V8 Capital Partners, Ingressive Capital, Y Combinator Management, LLC, Better Ventures, Fifty Years Industries, LLC, KdT Ventures LLC, Aera VC, Pioneer Fund
Legal advisers: not identified in the source record.
Source: announced 14 April 2020. Original announcement: techcabal.com.


